Dr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025. In the quarter to June 2026, revenue fell 14.4%, EPS fell 70.0%, free cash flow fell 143.4% and total debt rose 34.0%, each against the same quarter a year earlier.
Follow RDY
Dr. Reddy's Laboratories Ltd (RDY) EV/Sales
As of 16 October 2026, Dr. Reddy's Laboratories Ltd (RDY) trades at a EV/Sales of 2.9×. Over the past ten years it has ranged from 2.3× (August 2017) to 18.5× (October 2024); the current reading is higher than 25% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 3.2× | 12.01% |
| FY2025 | 2.8× | (17.55%) |
| FY2024 | 3.5× | 16.70% |
| FY2023 | 3.0× | (7.95%) |
| FY2022 | 3.2× | (17.50%) |
| FY2021 | 3.9× | 36.20% |
| FY2020 | 2.9× | (8.02%) |
| FY2019 | 3.1× | 16.42% |
| FY2018 | 2.7× | (19.06%) |
| FY2017 | 3.3× | 1.28% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.3× | 2.64% |
| Mar 2026 | 3.2× | 8.96% |
| Dec 2025 | 2.9× | 0.30% |
| Sep 2025 | 2.9× | (7.46%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTRS Viatris Inc. compare | 2.3× |
| HIMS Hims & Hers Health, Inc. compare | 2.7× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 2.8× |
| RDY Dr. Reddy's Laboratories Ltd | 2.9× |
| ELAN Elanco Animal Health Incorporated compare | 3.0× |
| NBIX Neurocrine Biosciences, Inc. compare | 4.1× |
| LNTH Lantheus Holdings, Inc. compare | 4.2× |
| ALKS Alkermes plc compare | 4.6× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 6.6× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)